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based, RNA interference-mediated therapeutic method to
significantly reduce the symptoms in the most frequently
used animal model of inflammatory bowel disease. This bacte-
rium-mediated RNA interference strategy was based on the ge-
nomically stable, non-pathogenic E. coli MDS42 strain, which
was engineered to constitutively produce invasin and the lister-
iolysin O cytolysin. These proteins enabled the bacteria first to
invade the colon epithelium and then degrade in the phago-
some. This allowed the delivery of a plasmid encoding small
hairpin RNA (shRNA) targeting tumor necrosis factor (TNF)
into the cytoplasm of the target cells. The expression levels of
TNF and other cytokines significantly decreased upon this
treatment in dextran sulfate sodium (DSS)-induced colitis,
and the degree of inflammation was significantly reduced.
With further safety modifications this method could serve as
a safe and side effect-free alternative to biologicals targeting
TNF or other inflammatory mediators.
INTRODUCTION
Inflammatory bowel disease (IBD) is an often severe, chronic disease
of the colon and small intestine. It is characterized by recurrent
inflammation of the gastrointestinal tract and has serious, potentially
lethal consequences. Its exact pathomechanism is not known, but it is
well established that cytokines play a central role in the development
of the disease.1 Several biologics and small-molecule inhibitors were
developed to inhibit the pathological activity of the various cytokine
pathways.2 Of those, monoclonal antibodies targeting tumor necrosis
factor (TNF) have become a cornerstone of IBD therapy.2,3 This treat-
ment option has several drawbacks that warrant the development of
alternative treatments, such as high cost, severe potentially lethal side218 Molecular Therapy: Methods & Clinical Development Vol. 20 March
This is an open access article under the CC BY-NC-ND license (httpeffects, and the fact that up to 50% of patients do not respond to, or
lose sensitivity to, this treatment over time.3 While some of the
patients resistant to anti-TNF antibody therapy respond to other
biologics, such as vedolizumab,4 significant portions of the resistant
cases are not responsive to these alternative therapies or become resis-
tant to those with time.5
An alternative approach to the antibody-mediated inhibition of
cytokine action is the use of genetically engineered bacteria that could
deliver inhibitory molecules, such as small hairpin RNA (shRNA),
directly into the target cells specifically against inflammatory media-
tors. This approach was successfully applied for downregulating
COX2 in experimental animals,6 and bacteria were also used to pro-
duce elafin inside the gut in order to reduce inflammation.7 In order
to directly target one of the cytokines centrally involved in the path-
omechanism of IBD, we developed a method to downregulate TNF
using a non-pathogenic Escherichia coli MDS42 strain with signifi-
cantly reduced evolvability.8,9 This strain was modified to constitu-
tively express invasin that allows bacteria to invade mammalian cells
by a b integrin-dependent manner and listeriolysin O that destroys
phagosomal membranes.6,10,11 These proteins enabled the bacteria
first to invade the colon epithelium and then degrade in the phago-
some and thus deliver the plasmid encoding shRNA targeting TNF
into the cytoplasm of the target cells. The shRNA silencing of TNF
significantly reduced intestinal inflammation in a widely used preclin-
ical model of IBD.2021 ª 2020 The Author(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Histological analysis of the colon obtained from the various
experimental groups
Representative histological fields at two magnifications (50 and 200) of the
various treatment groups as indicated. Vehicle, tap water-administered animal
group; siTNF, animals treated with modified E. coli MDS42 strains containing
psiTNF and invasive plasmids; DSS, colon specimen of the 2.5% DSS-treated
animals; DSS-siTNF, animals administered 2.5% DSS and treated by modified
E. coli MDS42 strains containing psiTNF and invasive plasmids.
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Dextran sulfate sodium (DSS)-induced colitis is one of the most
commonly used models of ulcerative colitis (UC).12 It induces inflam-
matory infiltration, a reactive shortening of the colon, and an increase
in the expression of inflammatory mediators. In our experiments, we
used two different concentrations, 2.5% and 3.5% DSS, to induce co-
lon inflammation of two different levels of severity. (For treatment
protocols, see Figure S1A.) As expected, both concentrations of
DSS induced a significant increase in the Nancy histological index
of UC,13 especially in the distal colon (Figures 1, 2A, and 2B). (For
inflammation scores and ulceration scores separately and changes
in the distal colon, see Figure S2.) DSS-induced inflammation is
accompanied by a reactive shortening of the colon. Both DSS concen-
trations induced a significant, shortening of the colon (Figures 2C and
2D). Finally, we isolated RNA from the whole colon and measured by
quantitative real-time PCR the expression level of several proinflam-
matory cytokines known to be elevated in IBD.1 3.5% DSS induced a
2-fold induction of TNF, a 100-fold induction of interleukin (IL)-1a,
an approximately 150-fold increase of IL-1b, and a 1.4-fold increase
of IL-6 (Figure 3). We also investigated the spatial distribution ofMolecularincreased TNF production in the colon by immunohistochemistry
(IHC). The diffuse pattern of increased expression suggested that
TNF was present both in epithelial cells as well as the immune cells,
such as macrophages, infiltrating the lamina propria (Figure 4).
Next, we tested whether the engineered bacteria were able to deliver to
the colon the pSuper plasmid and its derivative psiTNF vector, specif-
ically designed to silence TNF. In order to do this, the plasmid was
engineered to incorporate a mouse pgk promoter-driven gfp reporter
whose expression was detected using both specific PCR primers (Fig-
ure S3) and IHC (Figure 5). In particular, we assessed the capacity of
the engineered bacteria to deliver their cargo to macrophages, a key
inflammatory population that sustains colitis. Double staining with
anti-GFP and intestinal macrophage marker anti-Iba1 antibodies
shows the presence of GFP-expressing psiTNF plasmid in Iba1+ mac-
rophages in lymphoid aggregates and the lamina propria. GFP was
also expressed in mucosal epithelial cells (Figure 5). In order to test
the efficacy of the bacterium-delivered gene silencing system, the an-
imals with the DSS-induced IBD were then administered the E. coli
MDS42 bacteria specifically engineered to silence TNF. This treat-
ment had a dramatic effect on the DSS-induced colitis. The increase
of inflammatory mediators was significantly reduced. For each of the
inflammatory mediators measured, the expression returned to base-
line levels (Figure 3). Consequently, the Nancy index of UC was
also significantly reduced (Figures 2A and 2B). In the case of 2.5%
DSS treatment the inflammation score returned to baseline or near
baseline levels in the distal colon (Figure S2A). The ulceration score
increase was also reduced by 64% (Figure S2C). For the higher DSS
concentration (3.5%), both the inflammation and ulceration score
were reduced by 50% in the distal colon (Figures S2B and S2D).
Finally, the colon length shortening was also significantly reduced
to around the level seen in the control animals (Figures 2C and 2D).
As a control, we engineered the same bacteria carrying an empty vec-
tor, without the shRNA for TNF. This treatment did not reduce the
various measures of inflammation. Similarly, the colon length of
the animals treated with only pSuper and psiTNF plasmids (with in-
vasion plasmid) showed no significant alteration in comparison with
the control (water only) (Figures 2C and 2D). The mucosa thickness
did not show any significant change in the proximal or distal colon
regions for any of the above listed treatments (data not shown).
We also determined the DAI (disease activity index) value indicating
the severity of the inflammatory processes. Again, this was signifi-
cantly reduced by the engineered bacteria delivering the TNF-specific
shRNA responsible for TNF silencing (Figure 6).
We investigated changes induced by the various experimental condi-
tions in the gut microbiome by sequencing the 16S RNA V3 and V4
hypervariable regions. DSS-induced colitis significantly altered the
microbiome relative to control (Figures 7A and 7B). The microbiome
composition of the DSS-treated and the DSS + pSuper-treated ani-
mals were similar. The DSS-induced animals treated with the bacteria
carrying the shRNA for TNF, however, showed differences relative toTherapy: Methods & Clinical Development Vol. 20 March 2021 219
Figure 2. The Nancy histological index and colon
length of the 2.5% and 3.5% DSS-administered
animals
Histological analysis was carried out on formalin-fixed,
paraffin-embedded (FFPE) colon samples from experi-
mental groups, and the levels of inflammation and ulcer-
ation were scored as described in Materials and Methods.
(A) The Nancy histological index (UC) of the distal colon for
the various treatment groups with 2.5% DSS. (B) The
Nancy histological index (UC) of the distal colon for the
various treatment groups with 3.5% DSS. (C) Effect of
the modified E. coliMDS42 strains containing psiTNF and
invasive plasmids on the colon length in the treatment
group with 2.5% DSS. (D) Effect of the modified E. coli
MDS42 strains containing psiTNF and invasive plasmids
on the colon length in the treatment group with 3.5%DSS.
Vehicle: tap water-administered animal group; siTNF,
animals treated by modified E. coli MDS42 strains con-
taining psiTNF and invasive plasmids; DSS, colon spec-
imen of the DSS-treated animals; DSS-siTNF, animals
administered DSS and treated by modified E. coliMDS42
strains containing psiTNF and invasive plasmids; pSuper,
animals treated by modified E. coli MDS42 strains con-
taining pSuper (empty vector) and invasive plasmids;
DSS-pSuper, animals administered 2.5% DSS and
treated by modified E. coli MDS42 strains containing
pSuper (empty vector) and invasive plasmids. Data
represent the mean (SD). **p < 0.01, ***p < 0.001, ****p <
0.0001.
Molecular Therapy: Methods & Clinical Developmentthe disease model, as was demonstrated by a principal component
analysis (Figure 7B). These changes were driven by a reduction in
the abundance of the predominantly harmful, colitogenic Clostridia,
Desulfovibrio, and Parabacteroides (Figure 7A).
Encouraged by these results we also wanted to test whether the engi-
neered bacteria have a similar therapeutic effect when they are applied
after the disease had already developed. Animals were pretreated for
4 days with 2.5% DSS alone, and then the same treatment was
continued in the presence or absence of the therapeutic administration
of an engineered E. coli strain for 10 days (Figure S1B). The 35%–40%
colon length reduction induced by the DSS treatment was significantly
reduced to 15% in this treatment regimen as well (Figure 8A). DAI
measurements showed similar results. The DSS treatment alone
induced a DAI of 1.8, which was reduced to 0.3 by the therapeutic bac-
terial treatment (Figure 8B). Bacteria carrying the empty expression
vector had no effect on the DSS-induced disease (Figures 8A and 8B).
The therapeutic effect of the engineered E. coli was also reflected by
the reduced production of inflammatory mediators and increased
production of some of the anti-inflammatory cytokines (Figure S4).
Consequently, the Nancy index, the inflammation score, and the
ulceration score were significantly reduced (Figure S5).
DISCUSSION
During the past decade, engineered bacteria have emerged as a po-
tential “living” vehicle delivering both diagnostic and therapeutic220 Molecular Therapy: Methods & Clinical Development Vol. 20 Marchmolecules to the gastrointestinal tract.14 There are several ap-
proaches to the therapeutic exploitation of such a biological system
in terms of how directly the bacteria are interacting with the host
biological system. For example, bacteria were engineered to express
phenylalanine-metabolizing enzymes that, upon administration to
the digestive tract, would reduce the symptoms of phenylketon-
uria.15 In this case, the bacteria exert their therapeutic effect inside
the colon lumen by breaking down the phenylalanine introduced as
part of the diet. Similarly, lactic acid bacteria exerted their therapeu-
tic effect by producing elafin inside the gut, thereby reducing the
inflammation in the same preclinical model that we used in this
work.7 In these cases, both the bacteria and the therapeutic effectors
produced by them remained in the intestinal lumen and did not
invade the colon wall. These approaches, therefore, did not change
directly the intracellular levels of disease mediators. Considering the
often aggressive and therapy resistant nature of IBD,16 we hypoth-
esized that suppressing the expression of TNF inside the target cells
by delivering shRNA may exert a more dramatic therapeutic effect.
Efficient intracellular silencing of genes by engineered bacteria was
first demonstrated by Xiang et al.17 using E. coli-expressing invasin,
listeriolysin O cytolysin, and specific shRNA that could silence the
b-1 catenin gene in the colon of experimental animals. Spisni
et al.6 used a strategy to silence cyclooxygenase-2 to treat experi-
mental models of IBD by introducing the therapeutic bacteria in en-
emas. In the present study, we further adjusted this approach to
target one of the key mediators of IBD, TNF, using an orally appli-
cable delivery method. Our results suggest that this minimally2021
Figure 3. mRNA expression levels of
proinflammatory cytokines in vehicle treated
controls and 3,5% DSS induced colitis with and
without treatment with the modified E. coli MDS42
strains containing psiTNF
(A) TNF mRNA expression measured on distal colon
samples. (B) IL-1a mRNA expression measured on distal
colon samples. (C) IL-1b mRNA expression measured on
distal colon samples. (D) IL-6 mRNA expression
measured on distal colon samples. Vehicle, tap water-
administered animal group; DSS, colon specimen of the
3.5% DSS-treated animals; DSS-siTNF, animals admin-
istered 3.5% DSS and treated by modified E. coli MDS42
strains containing psiTNF and invasive plasmids. Data
represent the means (SD). *p < 0.05, **p < 0.01, ***p <
0.001.
www.moleculartherapy.orginvasive direct delivery of therapeutic modulators can cause a signif-
icant reduction of inflammation.
An appealing feature of this technology is its flexibility to target other
genes. There are rare forms of IBD, such as the very early onset IBD
(VEOIBD), in children.18 These patients often fail to respond to stan-
dard therapy, but the disease can be linked to well-defined mutations
or gene dysfunctions, which could form the basis of alternative ther-
apeutic approaches. Since the bacterial delivery technology presented
here can either suppress or overexpress specific genes, our delivery
method can be engineered to correct specific gene malfunctions.
There are serious safety concerns about the use of live bacteria in the
therapeutic setting. Bacteria may exchange genetic material with
other bacteria in the colon, which may lead to uncontrollable or diffi-
cult to control consequences.19 Therefore, in contrast to earlier ef-
forts, we used the genetically stable E. coli MDS 42 strain. More
than 20% of the genome of this strain, including transposons, was
deleted, and the recombination and conjugation abilities of the bacte-
ria were eliminated. Thus, the risk of horizontal gene transfers was
minimized. This risk could be further reduced by strategies that
would introduce mechanisms into the bacterial vectors leading to
their self-destruction within a few days in the colon but still able to
deliver the therapeutic effect.
MATERIALS AND METHODS
Animals
Adult (8–10 weeks old) male FVB/Ant mice were obtained from the
local colony bred at the Medical Gene Technology Unit (specific
pathogen-free [SPF] level) at the Institute of Experimental MedicineMolecular Therapy: Methods &(Budapest, Hungary). Animals were housed at
the minimal disease (MD) level, three to five
mice per cage, under controlled environmental
conditions: temperature, 21C ± 1C; humidity,
65%; 12-h light/12-h dark cycle; lights on at 7:00
AM. Mice had free access to rodent food and
water. All procedures were conducted in accor-dance with the guidelines set by the European Communities Council
(86/609/EEC/2 and 2010/63 Directives of European Community),
and the protocol was approved by the Institutional Animal Care
and Use Committee of the Institute of Experimental Medicine (Buda-
pest, Hungary) (permit no. PEI/001/29-4/2013).
UC model generation and animal treatment
In animal models, UC can be induced by DSS administration. The
experimental animals were 10-week-old FVB/Ant male mice. Mice
were treated with drinking water mixed with 2.5% and 3.5% DSS,
which was administered for 8 days or 14 days. The engineered bacte-
rial cells were grown in Luria-Bertani (LB) liquid medium at 37C.
The overnight bacterial culture was harvested by centrifugation and
washed twice with sterile tap water to eliminate the antibiotic contam-
ination (ampicillin and spectinomycin). Finally, the cell pellet was
suspended in sterile tap water and administered to the animals. The
engineered bacterial cells (2–5  108 colony-forming units [CFU])
and vehicle (sterile tap water) were administered daily by oral
gavages. During treatment, DAI values were observed. At the end
of the experiment, the animals were anesthetized and decapitated.
The length of the colon samples was measured by a digital caliper.
Colon samples were frozen and fixed for histological processing. In-
testinal contents were frozen.
Cloning procedures
The nucleotide sequences encoding shRNAS for efficiently silencing
the TNF were designed using Serial Cloner 2.6.1 software.
The forward (50-GATCCCCGACAACCAACTAGTGGTGCTTTTCA
AGAGAAAGCACCACTAGGTGGTTGTCTTTTTG-30) and reverseClinical Development Vol. 20 March 2021 221
Figure 4. Epithelial expression of TNF in DSS- and psiTNF-treated mice
(A and A0) Mice treated with vehicle show minimal expression of TNF-a in the distal
colon, limited to the apical surface of mucosal epithelial cells (A0, arrowheads).
(B and B0) After 7 days of DSS treatment, TNF production increases significantly,
where every cell in the epithelial lining of the intestinal mucosa (B, dashed line)
shows strong expression of TNF. (C and C0) Animals treated simultaneously with
psiTNF plasmid (GFP) and DSS exhibit moderate levels of TNF expression. In
contrast to animals not treated with the plasmid, distal colon of psiTNF-treated
mice display only non-continuous patches of epithelial TNF expression (C0, en-
circled areas).
Molecular Therapy: Methods & Clinical Development(50-AGCTCAAAAAGACAACCAACTAGTGGTGCTTTCTCTTGA
AAAGCACCACTAGTTGGTTGTCGGG-30) syntheticDNAoligonu-
cleotides (Microsynth Seqlab, Germany) were heated in annealing
buffer (100 mM NaCl, 50 mM HEPES [pH 7.4]) at 90C for 5 min
and allowed to cool to room temperature. The annealed double-
stranded synthetic DNA oligonucleotides were ligated into the
pSUPER.retro.neo GFP vector system (Oligoengine, USA) after
linearization with BglII and HindIII enzymes. During the cloning
steps, the ligation was heated to 90C for 5 min and allowed to
cool to room temperature. Subsequently, conventional heat shock
transformation was introduced into the prepared E. coli MDS42
strain. Recombinant bacteria were selected on LB medium containing
ampicillin. Plasmid constructs encoding the resulting psiTNF-a
(shRNA) precursors were verified by nucleotide sequence assay and
restriction enzyme digestion. Using the high-speed plasmid mini
kit (Geneaid), a plasmid was isolated from recombinant colonies
and digested with EcoRI and HindIII enzymes. The digested plasmids
were checked by agarose gel electrophoresis (1% agarose [Sigma],
1 Tris-boric acid EDTA buffer [pH 8.5]). The empty vector carries
a 1,000-bp-long insert, while the plasmids containing the ligated
synthetic oligonucleotides are 281-bp-long inserts that result after
double digestion. Plasmids from positive colonies were analyzed
by Sanger’s nucleotide assay using a specific sequencing primer
(50-GGAAGCCTTGGCTTTTG-30). The invasin gene of the pGB2-U
plasmid was verified by PCR amplification and restriction enzymatic
digestion PstI. PstI removes the fragment from the plasmid that con-
tains the invasin and listeriolysin.222 Molecular Therapy: Methods & Clinical Development Vol. 20 MarchQuantitative real-time PCR
Frozen tissue samples were homogenized in TRI reagent solution (Am-
bion, USA), and total RNA was isolated with a QIAGEN RNeasy mini
kit (QIAGEN, Valencia, CA, USA) according the manufacturers’ in-
structions. To eliminate genomic DNA contamination, DNase I treat-
ment was used and 100 mL of RNase-free DNase I (1 U of DNase)
(Thermo Scientific, USA) solution was added. Sample quality control
and the quantitative analysis were carried out by NanoDrop 2000
(Thermo Scientific, USA). Amplification was not detected in the RT-
minus controls. The cDNA synthesis was performedwith a high-capac-
ity cDNA reverse transcription kit (Applied Biosystems, USA). Primers
for the comparative Ct experiments were designed by the Primer Ex-
press 3.0 program and Primer-BLAST software. The primers (Micro-
synth, Balgach, Switzerland) were used in the real-time PCR reaction
with Fast EvaGreen qPCR master mix (Biotium, USA) on an ABI Ste-
pOnePlus instrument (AppliedBiosystems,USA)and are listed inTable
S1. The gene expression was analyzed by the ABI StepOne 2.3 program.
The amplicon was tested bymelt curve analysis on anABI StepOnePlus
instrument. Experiments were normalized to gapdh expression.
Library construction for Illumina MiSeq sequencing of the 16S
rRNA amplicons
Standard library preparation was performed according to the Illumina
(SanDiego,CA,USA)16Smetagenomic sequencing librarypreparation
protocol (15044223 rev. B). TheV3 andV4 hypervariable regions of the
bacterial 16S rRNAgenewere sequencedwith IlluminaMiSeqbenchtop
sequencer generating amplicons of460 by using the universal primer
set as follows: 341F (50-CCTACGGGNGGCWGCAG-30) and 785R
(50-GACTACHVGGGTATCTAATCC-30) primers flanked by Illu-
mina overhang adaptor sequences (forward overhang, 50-TCGTC
GGCAGCGTCAGATGTGTATAAGAGACAG-30; reverse overhang,
50-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-30). Af-
ter completion of the amplicon PCR with 2 KAPA HiFi HotStart
ReadyMix, dual indexing of the 96 with adaptor sequences (i7-N7xx,
12 items; i5-S5xx, 8 items) was performed using the Illumina Nextera
XT index kit (FC-131-1001/2). PCR cleanups and amplicon size selec-
tions were carried out with KAPA Pure Beads (KAPA Biosystems)
based on the technical data sheet (KR1245, v3.16) of the manufacturer,
resulting in final 580- to 630-bp libraries. Every time, verifications
were done with PCR Agilent D1000 screen tapes (5067-5582) and
D1000 reagents (5067-5583). The 16S amplicon libraries for each sam-
ple were quantified with qPCR, normalized with respect to amplicon
sizes, and pooled into a single library in equal molar quantities. Finally,
5 mL of the pooled 4 nMDNA library pool was prepared for sequencing
on the Illumina MiSeq platform. The library pool was denatured with
0.2 M NaOH and diluted to 8 pM final concentration. Sequencing
was carried out with MiSeq reagent kit v3 (618 cycle; MS-102-3003)
following the manufacturer’s protocols (Illumina, San Diego, CA,
USA). All data are publicly available and can be accessed through the
PRJNA687617 from the NCBI Sequence Read Archive (SRA).
Sequencing read preparation for downstream analysis
Paired-end reads were demultiplexed by the integrated
software of the Illumina MiSeq sequencing machine. The2021
Figure 5. Immunohistochemical analysis of the
distal colon of DSS-administered (8 days), psiTNF-
treated (4 days) animals
(A) Distal colon of DSS-administered (8 days), psiTNF-
treated (4 days) animals (mucosa, submucosa): psiTNF
plasmid (GFP), Iba1+ mucosal macrophages (arrows), and
epithelial cells (arrowheads). (B–D) Distal colon of DSS-
administered (8 days), psiTNF-treated (4 days) animals
(lymphatic aggregate in mucosa): psiTNF plasmid (GFP);
GFP/IBA double-positive macrophages (arrowheads). (C
and D) High-magnification images: Iba1+GFP+ (arrow-
heads) and Iba1+GFPmacrophages (arrow in D). (E and F)
Distal colon of DSS-administered (8 days), psiTNF-treated
(4 days) animals (lymphatic aggregate in mucosa): psiTNF
plasmid (GFP); GFP is expressed in CD45+Iba1+ mucosal
macrophages (arrowheads in E); only pycnotic and ramified
CD45/Iba1 double-positive macrophages express GFP,
whereas CD45+Iba1 lymphocytes of round morphology
show no plasmid incorporation (F). (G–I) Distal colon of
DSS-administered (8 days), psiTNF-treated (4 days) ani-
mals (mucosa); psiTNF plasmid (GFP); F4/80+ mucosal
macrophages and epithelial cells show strong TNF pro-
duction (G). (H and I) Expression of TNF and GFP of F4/80+
mucosal macrophages in consecutive sections.
www.moleculartherapy.orgFastQ files were imported into the QIIME 2 pipeline (https://
qiime2.org/) according to the “Atacama soil microbiome”
tutorial. Residual adaptor sequences (50-CTGTCTCTTATAC
ACATCT-30) were trimmed from the 30 end of the reads
with Cutadapt software integrated in the QIIME 2 pipeline.
Quality trimming was performed by using DADA2 software,20
and the denoising parameters were set as follows: forward read
length was set to 299 bases; for the reverse reads, the length wasMolecular Therapy: Methods &set to 249 bases. No trimming from the start
of the reads was applied.
Operational taxonomic unit (OTU) generation
Multiple sequence alignment was performed
with MAFFT software,21 and reads weretaxonomically classified using a naive Bayesian classifier trained
with the Greengenes reference database (v13_8) by selecting
mapping points according to the forward-reverse primer set
that was used for amplifying the 16S V3–V4 regions of the
bacterial community (341F, 806R). Aligned sequences were
clustered into OTUs with a threshold level of 99% sequence
identity. Singletons were discarded in order to reduce the
likelihood of sequence artifacts interfering with fartherFigure 6. Effects of DSS-induced colitis on the
disease activity index (DAI) of colitis
(A) Effect of the modified E. coliMDS42 strains containing
psiTNF and invasive plasmids on the DAI. The animals
were administered 2.5% DSS. (B) Biological effect of
modified E. coli MDS42 strains containing psiTNF and
invasive plasmids were evaluated considering the DAI of
3.5% DSS-induced colitis. DSS, colon specimen of the
DSS-treated animals; DSS-siTNF, animals administered
DSS and treated by modified E. coli MDS42 strains con-
taining psiTNF and invasive plasmids; DSS-pSuper, ani-
mals administered DSS and treated by modified E. coli
MDS42 strains containing pSuper (empty vector) and
invasive plasmids. Data represent the mean (SD). *p <
0.05, **p < 0.01.
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Figure 7. Sequencing of the 16S RNA V3 and V4 hypervariable regions
Characterizing microbiome changes by sequencing the bacterial 16S RNA V3 and V4 hypervariable regions in the vehicle treated control, DSS induced colitis, and the DSS
induced colitis that were treated with the modified E. coliMDS42 strain that either carried an empty plasmid or the psiTNF. (A) the relative abundance of the various bacterial
genera; (B) Differences in the microbioime composition as expressed by the weighted principal component analysis (wPcoA).
Molecular Therapy: Methods & Clinical Developmentdownstream analysis. A phylogenetic tree was constructed with a
FastTree plugin.22
Biodiversity analysis
For sample normalization, 8,300 sequencing (read) depths were
set. Beta diversity analysis involved measuring weighted/un-
weighted UNIFRAC distances.23 For visualization of beta diversity224 Molecular Therapy: Methods & Clinical Development Vol. 20 Marchmatrices, principal coordinate analysis (PCoA) plots were gener-
ated using the EMPeror24 plugin.
Data visualization
For data mining (preparation), the QIIME 2 pipeline was used.
QIIME artifact files were exported from the pipeline resulting
BIOM files that were converted to TSV files, which were used withFigure 8. Effect of the 4 + 10 days of 2.5% DSS-
induced colitis on colon length and the DAI of colitis
(A) Effect of the modified E. coli MDS42 strains containing
psiTNF and invasive plasmids on colon length. The animals
were administered 2.5% DSS. (B) Biological effect of
modified E. coli MDS42 strains containing psiTNF and
invasive plasmids were evaluated considering the DAI of
2.5% DSS-induced colitis. DSS, colon specimen of the
DSS-treated animals; DSS-siTNF, animals administered
DSS and treated by modified E. coli MDS42 strains con-
tainingpsiTNF and invasiveplasmids; DSS-pSuper, animals
administered DSS and treated by modified E. coli MDS42
strains containing pSuper (empty vector) and invasive plas-
mids. Data represent the mean (SD). *p < 0.05, **p < 0.01.
2021
www.moleculartherapy.orgexternal visualization packages. Pie charts were constructed with R
programming language (https://www.R-project.org)25 using the
ggplot2 package (http://ggplot2.org).26
GFP tracing in the colon
Total RNA was isolated and cDNA synthesis was performed from the
frozen colon samples. The gfp expression in the colon tissue was
demonstrated by PCR using specific oligonucleotide primers (for-
ward, 50-GGA CGA CGG CAA CTA CAA GA-30; reverse, 50-AAG
TCG ATG CCC TTC AGC TC-30). The PCR product was separated
and stained on agarose gel.
Pathology (histology)
Formalin-fixed colon samples were processed and embedded in
paraffin using the standard protocol. Sections of 4 mm were stained
with hematoxylin and eosin. Slides were analyzed by an expert
pathologist in a blinded manner using the Nancy histological index
for UC.13
Histological procedures
For immunofluorescence (IF), distal colon samples of adult (8- to
10-week-old) FVB/Ant mice, treated with 2.5% DSS and psiTNF-a
plasmid, were fixed in 4% paraformaldehyde (PFA) in PBS for 24 h.
After extensive washing in PBS, the samples were infiltrated with
15% sucrose/PBS overnight at 4C. The medium was changed to
7.5% gelatin containing 15% sucrose at 37C for 2 h, and the tissues
were rapidly frozen at 60C in isopentane (Sigma). Frozen sections
were cut at 10 mmwith a Shandon cryostat for confocal laser-scanning
microscopy, collected on poly-L-lysine-coated slides (Sigma).
Immunofluorescence and image analysis
IF was performed as previously described.27 Briefly, primary anti-
bodies anti-GFP (R&D Systems), anti-TNF-a (Abcam), anti-Iba1
(Invitrogen), and anti- F4/80 (Invitrogen) were diluted 1:200 in 1%
PBS-BSA. For IF, frozen sections were incubated with primary anti-
bodies overnight at 4C, followed by relevant secondary antibodies
(Alexa Fluor 647-, 546-, and 488-conjugated anti-rabbit immuno-
globulin G [IgG] and Alexa Fluor 488-conjugated anti-goat IgG,
from Invitrogen) used for 1 h at room temperature (RT). Cell nuclei
were visualized by DAPI (40,6-diamidino-2-phenylindole; Vector
Laboratories). Sections were covered with aqueous Poly/Mount (Pol-
ysciences, Warrington, PA, USA) and examined with a Zeiss LSM 780
laser-scanning confocal microscope (Zeiss). The ZEN software pack-
age (black edition, Zeiss) was used for the scanning of 4-mm and
1.8-mm-thick optical slices of 10 megapixel (MP) resolution for
low- and high-magnification images, respectively. Images were
compiled with ImageJ and Adobe Photoshop CS6 software packages.
Statistical analysis
Data are expressed as means ± SD. The data were first subjected to a
Kolmogorov-Smirnov normality test. Data passing this test were
analyzed by one-way ANOVA followed by the Tukey’s post hoc
test. When the data showed non-Gaussian distribution, the Krus-
kal-Wallis test was used. Statistical analysis was performed usingMolecularGraphPad Prism version 6 software (GraphPad, USA). p %0.05
was considered significant.
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